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Esthesioneuroblatoma (Olfactory neuroblastoma) is a rare malignant neoplasm arising from the olfactory epithelium
with bimodal age distribution between with first peak in second decades and second peak in sixth decade.
Proptosis due to esthesioneuroblastoma is one of the rare causes. They have a long natural history characterized by
frequent local or regional recurrence. Computed tomography and magnetic resonance imaging are the imaging
modalities for diagnosing these tumors. A multidisciplinary approach with surgery and radiation therapy is an
excellent treatment options for these tumors with chemotherapy being used to treat advanced or recurrent
disease.
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Esthesioneuroblastoma (olfactory neuroblastoma) is a rare
neuroectodermal malignant neoplasm that originates from
the olfactory sensory epithelium [1-3]. It accounts for upto
5.0% of malignant tumors of the nasal cavity. Berger et al.
in 1924 was first to describe this disease. The incidence
curve for this disease has a bimodal shape with the first
peak in the 2nd decade and 2nd peak in 6th decade
with roughly equal sex distribution [2]. Patients present
with nonspecific symptoms of nasal obstruction, epistaxis,
headache, pain, visual disturbances, anosmia. Owing to
the nonspecific nature of the presenting symptoms, pa-
tients often have a long history prior to diagnosis [3].
Tumors involving the orbital area generally present
with epiphora, decreased visual acuity and proptosis
[4]. We report a case of esthesioneuroblastoma in 60
years old male who presented with proptosis and nasal
obstruction, diagnosed on computed tomography.Case report
A 60 years old male presented to with complaints of
nasal obstruction, nasal bleeding and bulging of left eye
with decreased vision for 1.5 years. He also noticed a
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reproduction in any medium, provided the ormonths and associated headache and neck pain. There
was insignificant past history and family history. On
systemic examination, there was loss of smell sensation.
Local examination revealed a diffuse, firm, nontender
swelling with ill-defined margins over the nasal bridge,
glabella and over left maxillary region. There was no
rise in local temperature. Pinkish mass was visible in
both nostrils with purulent nasal discharge. There was
proptosis of left eye and mild lateral deviation with lim-
ited eyeball movement; however visual acuity was nor-
mal. There is no evidence of lymphadenopathy. Blood
profile demonstrates normal limits of complete blood
count, renal function test and liver function test.
Computed tomography (CT) scan of paranasal sinuses
including orbit was performed in axial section with cor-
onal and sagittal reconstructions. CT revealed large, ill-
defined, heterogeneously enhancing soft tissue density
mass in both nasal cavities and ethmoid sinuses with
destroyed nasal septum (Figure 1A, 1B). There was de-
struction of medial wall of left maxillary sinus and left
lateral nasal wall with extension into left maxillary antrum.
Laterally, the mass extended into the left infratemporal
region with destruction of the postero-lateral wall of
left maxillary sinus (Figure 1C, 1D, 2A). There was also
destruction of medial wall of left orbit with intraorbital
extension causing antero-latero-inferior displacement
of the eyeball resulting in proptosis (Figure 1A, 2B).
The mass extended superiorly involving frontal sinuses;td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CT images in soft tissue window showing mass in ethmoid sinus and nasal cavity extending into the left orbit. A & B: Axial
section CT image showing heterogeneously enhancing soft tissue density mass in bilateral ethmoid sinuses and both nasal cavities with bony
destruction and extension into left orbit causing proptosis. C & D: Axial and coronal section CT images showing lateral extension of the mass into
left infratemporal region with destruction of the postero-lateral wall of left maxillary sinus.
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intracranial extension. Inferiorly, there was destruction
of hard palate with intraoral extension (Figure 1C, 1D).
Posteriorly, it was extending into nasopharynx through
choana and destruction of anterior sphenoid sinus wall
extending into sinus (Figure 2A, 2B).
Histopathology revealed monomorphic malignant round
cell tumour with rossette formation, consistent with es-
thesioneuroblastoma. Patient was advised for chemother-
apy/radiotherapy and was referred to oncology institute.Figure 2 CT images in bone window showing bony destruction. A & B
and postero-lateral wall of left maxillary sinus, left lateral wall of nasal cavity, nDiscussion
Esthesioneuroblastoma has been reported to originate from
sphenopalatine ganglion, vomeronasal organ of Jacobson,
neuroepithelial cells of the olfactory membrane, the ectopic
olfactory epithelium in the nasal mucosa and the amine
precursor uptake and decarboxylation cells [1,2]. It is a lo-
cally infiltrating malignant neoplasm; frequently invades
the skull base, orbit and adjacent soft tissue from the
typical “cribriform” site. In our patient, the neoplasm has
infiltrated the left orbit through destruction of medial: Axial section CT images (bone window) showing destruction of medial
asal septum, ethmoid sinus and medial wall of left orbit by the mass.
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metastases are seen in about 14–38% of cases at the time
of diagnosis; cervical lymph nodes, lung and bone being
the frequently involved sites [4]. Esthesioneuroblastoma
should be differentiated from other malignant tumors in
anterior skull base.
CT and magnetic resonance imaging (MRI) are helpful
to identify the margin and spread approaches of the
tumor. Fine-cut CT scan (3 mm slice thickness) with
direct coronal imaging is the initial radiological study of
choice [5]. On CT scan, the tumor usually present with a
heterogeneous mass, sometimes with focal necrosis or
calcification. The paranasal sinuses and anterior skull
base are often destroyed, while the clivus is intact. It ap-
pears as isointense on T1-weighted and hyperintense on
T2-weighted MR images with heterogeneous enhance-
ment on gadolinium contrast study. MRI help to differ-
entiate tumour from obstructed secretions in paranasal
sinuses, determining meningeal and extradural spread
and to detect perineural spread [5,6]. Angiography dem-
onstrates tumour blush in majority of cases [6].
There are several staging systems described for olfactory
neuroblastoma; Kadish system [7] has been the frequently
used staging system with good prognostic correlation. It
has divided the tumors in three stages: Stage A- tumors
restricted to the nasal cavity; Stage B- tumors involving
the nasal cavity and paranasal sinuses and Stage C- tumors
extending to beyond the paranasal sinuses (orbit, skull
base or metastasis).
Differential diagnosis of esthesioneuroblastoma includes
inverting papilloma, squamous cell carcinoma, adenocar-
cinoma, sinonasal undifferentiated carcinoma, hemangioma
and metastasis. In addition to imaging, histopathological
correlation is must in making diagnosis [8]. Esthesioneu-
roblastomas are histologically similar to adrenal or sympa-
thetic ganglionic neuroblastomas and retinoblastomas [9].
On histopathology, the presence of fibrillary intercellular
background along with Homer-Wright rosettes is consid-
ered to be diagnostic of esthesioneuroblastoma [10].
Open craniofacial resection or endonasal endoscopic re-
section is done for stage A and B tumors. Chemotherapy
is usually implemented in patients with locally advanced,
metastatic or recurrent disease [11-14]. The commonly
used chemotherapy combinations are cyclophosphamide
plus vincristine and cisplatin-based regimens [15]. The
combination of surgery and radiotherapy is the most fre-
quent treatment approach with highest cure rates, how-
ever definitive radiotherapy as a conservative management
is also used. Despite definitive local therapy, local recur-
rence and distant metastases have been reported with the
metastasis being 25.0-50.0% of cases. In patients with
recurrent or metastatic olfactory neuroblastoma, chemo-
therapy is therefore often implemented. Radiotherapy is
usually adopted as an adjuvant following surgery, espe-cially for cases with neck metastasis or as a neoadjuvant
before surgery [14,16]. Compared with other sinonasal
malignancies, the prognosis of esthesioneuroblastoma is
much better, with a disease-free survival at 5 years of
more than 80.0% [17].
Conclusion
In conclusion, clinicians should be aware of this malignant
disease and proptosis should be considered as one of the
differential diagnosis of esthesioneuroblastoma. Computed
tomography and magnetic resonance imaging are the
modalities of choice in diagnosing, looking for extent
and staging of tumor in esthesioneuroblastoma. A mul-
tidisciplinary approach with surgery and radiation ther-
apy is the treatment options for these tumors with
chemotherapy being used to treat advanced or recur-
rent disease.
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